Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 5/20 | 0.60 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.60 |
| ▸ | BCHE | P06276 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.52 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22864072 | 0.82 | ADRB2 (0.56) | ADRB2DNM1BCHEACHEADRB1 | |
| SCHEMBL22864046 | 0.79 | ADRB2 (0.53) | ADRB2DNM1ADRB1CYP2C19DRD3 | |
| SCHEMBL22864090 | 0.77 | ADRB2 (0.48) | ADRB2DNM1ADRB1HIF1ACYP2C19 | |
| SCHEMBL11088171 | 0.76 | ADRB2 (0.61) | ADRB2ADRB1HIF1ACYP2C19HTR1A | |
| Carazolol SCHEMBL29354289 | 0.76 | ADRB2 (1.00) | ADRB2DNM1ADRB1ABCB11HTR1A | |
| Carazolol SCHEMBL6511163 | 0.76 | ADRB2 (1.00) | ADRB2DNM1ADRB1ABCB11HTR1A | |
| Carazolol SCHEMBL77903 | 0.76 | ADRB2 (1.00) | ADRB2DNM1ADRB1ABCB11HTR1A | |
| Carazolol SCHEMBL77901 | 0.76 | ADRB2 (1.00) | ADRB2DNM1ADRB1ABCB11HTR1A | |
| SCHEMBL20800181 | 0.75 | IMPDH2 (0.53) | ADRB2DNM1BCHEACHEIMPDH2 | |
| Carazolol SCHEMBL10568418 | 0.75 | ADRB2 (0.98) | ADRB2DNM1ADRB1ABCB11HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2022-10-06 | — | — | US | disclosed |
| WO-2021003161-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885DNM1 2176/4885BCHE 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.